Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + pyrotinib + taxane
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy regimen consisting of trastuzumab (a monoclonal antibody targeting HER2), pyrotinib (an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor), and a taxane (typically docetaxel or paclitaxel). This regimen employs dual HER2 blockade by simultaneously targeting the extra- and intra-cellular domains of HER2, along with a taxane chemotherapy agent. The combination has shown significant efficacy in HER2-positive breast cancer, particularly in metastatic and neoadjuvant settings.
- Brand names
- AitinibHerceptin
- Other names
- trastuzumab + pyrotinib + taxenePyrotinib + Trastuzumab + Taxane
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))PDGFRB (Platelet-derived growth factor receptor beta)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on trastuzumab + pyrotinib + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + pyrotinib + taxane.